SCHEMBL4078442

SCHEMBL4078442

CC(C)NC(=O)N1CC(OC(c2ccc(Br)cc2)c2ccc(Br)cc2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.46
CNR1 P21554 1/20 0.46
POLB P06746 1/20 0.43
SLC6A4 P31645 3/20 0.41
SLC6A3 Q01959 3/20 0.41
KDM4E B2RXH2 1/20 0.40
FAAH O00519 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
GRM5 P41594 1/20 0.39
GRM7 Q14831 1/20 0.39
GRM3 Q14832 1/20 0.39
TACR1 P25103 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HSP90AA1 P07900 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1C Q13936 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4080289 0.84 NAAA (0.43) NAAASLC6A4SLC6A3KDM4EFAAH
SCHEMBL4075563 0.83 CNR1 (0.47) NAAACNR1POLBSLC6A4SLC6A3
SCHEMBL4077629 0.82 CNR1 (0.48) NAAACNR1SLC6A4SLC6A3CYP1A2
SCHEMBL4079546 0.81 CNR1 (0.50) NAAACNR1CYP1A2KMT2A
SCHEMBL4078545 0.81 NAAA (0.43) NAAACNR1SLC6A4SLC6A3KDM4E
SCHEMBL4075740 0.79 KMT2A (0.45) NAAACNR1POLBGAAKMT2A
SCHEMBL4084625 0.77 CNR2 (0.47) NAAAPOLBKDM4ETSHRALDH1A1
SCHEMBL4083302 0.75 NAAA (0.48) NAAACNR1FAAHCACNA1HCACNA1C
SCHEMBL24454992 0.75 CNR2 (0.40) NAAAPOLBSLC6A4SLC6A3KDM4E
SCHEMBL24433940 0.75 NAAA (0.38) NAAASLC6A4SLC6A3KDM4EFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620395-B1 AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS VERNALIS RES LTD (GB) 2009-12-30 EP disclosed
US-7504522-B2 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders VERNALIS RESEARCH LIMITED (GB) 2009-03-17 US disclosed
US-20070054891-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders VERNALIS RESEARCH LIMAITED (GB) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054891-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders CNR1, CNR2, GPR119 NAAA 175/4885CNR1 1/4885POLB 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.